James Benson, Chairman
Mr. Benson has served as the Chairman of the Cytomedix Board from July 2008 and as a Director of the Cytomedix Board since November 2004. Mr Benson recently retired from the Advanced Medical Device Association (AdvaMed, formerly known as The Health Industry Manufacturers Association, HIMA), where he served as Executive Vice President for Technical and Regulatory Affairs. Prior to that, he held numerous senior positions at the Food and Drug Administration (FDA) over a 20 year period eventually retiring as director of the Center for Devices and Radiological Health (CDRH). Mr. Benson earned a Bachelor of Science degree in Civil Engineering from the University of Maryland and a Master of Science degree in Nuclear Engineering from the Georgia Institute of Technology.

David Crews, Director
Mr. Crews has served as a Director of the Cytomedix board since September 2001. Mr. Crews is Executive Vice President of Crews and Associates, Inc., a brokerage house located in Little Rock, Arkansas. Mr. Crews has worked at Crews & Associates for more than 16 years, specializing in the fixed income markets. He is a former partner of All American Leasing, a municipal finance firm, and also serves as Vice President, Secretary, and Treasurer of CHASC, Inc., an entity that acquired Smith Capital Management (an investment advisory firm).

Martin Rosendale, Chief Executive Officer
Mr. Rosendale joined Cytomedix, Inc. in March 2008 as COO and he was appointed Chief Executive Officer in July 2008. Prior to joining Cytomedix, Mr. Rosendale was Chief Executive Officer of Core Dynamics, Inc. where he managed their Israel based R&D program and initiated U.S. commercial operations for cryobiology and cell lyophilization technologies. Mr. Rosendale has more than 24 years of specialty medical experience. He has held leadership positions for the past 15 years with American Red Cross, SangStat, North American Vaccine and ZLB Bioplasma, in addition to serving on the boards of the Transplant Recipients International Organization and the American Red Cross Biomedical Services, San Jose Region. Mr. Rosendale earned a Bachelor of Science degree in Microbiology from California State University.

David Jorden, Executive Director
Mr. Jorden joined Cytomedix, Inc. in September 2008. Prior to joining Cytomedix, Mr. Jorden was responsible for equity portfolio management at Morgan Stanley's Private Wealth Management group and previously served as CFO at Genometrix, Inc., a private genomics/life sciences company. Mr. Jorden serves on the Board of Opexa Therapeutics, Inc., PLx Pharma, Inc., and DLush, a San Diego based deluxe beverage company. Mr. Jorden earned a Master of Management from the Kellogg School of Management at Northwestern University and a BBA from the University of Texas at Austin. He holds both CFA and CPA designations.

Mark T. McLoughlin, Director
Mark T. Mcloughlin has served as a Director since June 7, 2004. Mr. McLoughlin currently serves as a Senior Vice President for VWR International, a global distributor of laboratory supplies, equipment and services to the pharma, biotech, industrial and clinical laboratory. In this capacity, he has responsibility for the sourcing and marketing functions for North America. Prior to joining VWR International, he was Senior Vice President, Chief Marketing Officer for Cardinal Health based in Rolle, Switzerland. Prior to joining Cardinal, he was vice president of commercial operations for Norwood Abbey Ltd., an Australian-based medical technology company. Earlier, he was President of North American operations for Ion Beam Application, Inc., a Belgium-based global medical technology company. His executive career experience also includes Mallinckrodt, as well as positions with other healthcare companies.

Stephen N. Keith, MD, Director
Dr. Keith has served as a Director of the Cytomedix board since September 2008. Dr. Keith is President and Chief Operating Officer of Panacea Pharmaceuticals, Inc., and he serves as Chair of the Board of Directors of NanoVec, Inc., an early-stage vaccines development company. Dr. Keith has held a range of senior management positions in the pharmaceutical and biotechnology industries including Antex Biologics Inc., North American Vaccine, Inc., and Merck & Co., Inc. Dr. Keith earned his B.A degree from Amherst College, his M.D. degree from the University of Illinois and his M.S. in Public Health from UCLA. Dr. Keith is a Fellow of the Academy of Pediatrics and a Diplomate of the American Board of Pediatrics.

C. Eric Winzer, Director
Mr. Winzer joined Cytomedix, Inc. in January 2009. He has served as Executive Vice President and Chief Financial Officer of Avalon Pharmaceuticals since July of 2007, and prior to joining Avalon, Mr. Winzer was with Invitrogen Corporation. From 1980 to 2000, Mr. Winzer held various financial positions of increasing responsibilities at Life Technologies and Genex Corporation. Mr. Winzer earned a B.A. in Economics and Business Administration from McDaniel College and an M.B.A. from Mount Saint Mary’s University.
© 2009 Cytomedix.  All Rights Reserved. Site Map | Terms & Conditions